$0
Thoughts on Poseida’s Strategic Global Collaboration with Roche
On Wednesday, August 3, Poseida announced (press release / presentation) a strategic global collaboration with Roche to develop and commercialize existing and novel allogeneic cell therapies for hematologic indications. Of note, Poseida will receive $110M upfront and further milestone payments potentially exceeding $6B in aggregate value. Below, Celltelligence provides insights on Roche’s shift in interest regarding cell therapies, while discussing Poseida’s partnering strategy.